Table 1.
Baseline Characteristics of the 212 patients with chronic liver disease.
| Control (n = 80) | Chronic liver disease | ||
|---|---|---|---|
| Hepatitis (n = 140) | Cirrhosis(n = 72) | ||
| Average age, years (range) | 41.86(20,70) | 45.34(15,86) | 48.94(19,74)a |
| Gender | |||
| Male (%) | 53(66.25) | 79(56.43) | 55(76.39) |
| Female (%) | 27(33.75) | 61(43.57) | 17(23.61)b |
| Serum ALT level (U/L),(Median, range) | 20.70(15.33,25.88) | 28.25(17.38,50.60)a | 29.25(20.73,48.50)a |
| Serum AST leve (U/L),(Median, range) | 19.90(16.98,22.68) | 26.75(20.65,41.68)a | 35.25(24.13,54.33)ab |
| APRI score (Median, range) | 0.24(0.18,0.31) | 0.49(0.34,0.77)a | 1.41(0.64,2.62)ab |
| PLT(× 109/L) (Median, range) | 232.00(197.75,281.50) | 174.50(135.25,213.75)a | 88.00(57.25,129.75)ab |
| HBsAg (> 0.4 IU/mL) | |||
| Negative (%) | 80(100) | 31(22.14) | 7(9.72) |
| Positive (%) | 0(0) | 109(77.86)a | 65(90.28)ab |
| FIB-4 Index (Median, range) | 0.75(0.57,0.98) | 1.46(0.93,2.22)a | 4.04(1.89,7.86)ab |
| TET3 ng/mL | 127.58(96.99,163.7) | 268.10(133.97,900.56)a | 1148.09(362.64,1451.11)ab |
aP < 0.05 versus control; bP < 0.05 versus hepatitis.
Abbreviations:ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIB-4, fibrosis-4; APRI, AST to platelet ratio Index; PLT, platelet count; HBsAg, Hepatitis B surface antigen; TET3, Ten-eleven translocation protein 3.